New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 10, 2014
09:31 EDTVRX, NSRGYValeant completes filler, toxin asset sale to Galderma
Valeant Pharmaceuticals (VRX) announced it has completed the sale to Galderma of all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant for $1.4B in cash, pursuant to the previously announced agreement with Nestle (NSRGY) which recently completed its acquisition of Galderma.
News For VRX;NSRGY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 30, 2015
07:29 EDTVRXValeant selected as lead bidder to acquire Dendreon, Provenge for $296M
Subscribe for More Information
05:20 EDTVRXDendreon reaches agreement for Valeant to serve as 'stalking horse bidder'
Subscribe for More Information
January 22, 2015
05:57 EDTVRXActavis, Valeant raise prospects of more healthcare deals, Financial Times says
Subscribe for More Information
January 21, 2015
12:30 EDTVRXGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information
January 20, 2015
06:51 EDTNSRGYNestle to invest about $140M in Egypt over next few years, Reuters says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use